Cargando…
DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform
It is estimated that approximately 22,000 Americans will be diagnosed with tumor of the brain or nervous system in 2010. Among primary brain tumors, approximately 60% are gliomas, the most common and most malignant of which is glioblastoma multiforme (GBM).The DecisionDx-GBM test is a multigene expr...
Autores principales: | Allingham-Hawkins, Diane, Lea, Andrew, Levine, Susan |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957243/ https://www.ncbi.nlm.nih.gov/pubmed/20972474 http://dx.doi.org/10.1371/currents.RRN1186 |
Ejemplares similares
-
BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer
por: Lea, Andrew, et al.
Publicado: (2010) -
KIF6 p.Trp719Arg Testing to Assess Risk of Coronary Artery Disease and/or Statin Response
por: Allingham-Hawkins, Diane, et al.
Publicado: (2010) -
ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer
por: Allingham-Hawkins, Diane, et al.
Publicado: (2010) -
Oncotype DX tumor gene expression profiling in stage II colon cancer: Application: Prognostic, risk prediction
por: Webber, Elizabeth M., et al.
Publicado: (2010) -
Use of Oncotype DX in Women with Node-Positive Breast Cancer
por: Ishibe, Naoko, et al.
Publicado: (2011)